Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03853317
Title Evaluate Efficacy of Avelumab, haNK and N-803 in Subjects With Progressed MCC on or After Checkpoint Inhibitor Therapy.
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Altor BioScience
Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.